Brentuximab Vedotin is used to treat certain types of lymphomas. Learn how to use the medication, its common side effects, special precautions to watch out for, and more.
This medication is also known as Brentuximab.
Brentuximab Vedotin is used to treat certain types of lymphomas, such as Hodgkin lymphoma, systemic anaplastic large cell lymphoma and certain T-cell lymphomas.
The medication works by targeting the CD30 protein that is found on the surface of the cancer cells. When it binds to the CD30 protein, it delivers a chemotherapy drug into the cancer cell to kill it.
It may be given on its own, or in combination with other chemotherapy medications.
Brentuximab Vedotin is injected into the vein as an infusion, over 30 minutes.
It is given once every 3 weeks.
The table below will list some of the common side effects as well as the rare but serious side effects.
Side Effect | Management |
Infusion-related reaction
|
|
Decrease in white blood cell count. This may increase your chances of getting an infection.
|
|
Decrease in platelet count. Low platelet levels can increase your chance of bleeding.
|
|
Decrease in the number of red blood cells (anaemia) As your red blood cells help to carry oxygen to the different parts of your body, this may cause you to feel tired more easily. |
|
Nerve problems You may experience numbness or tingling sensation in the hands or feet. This side effect usually affects the fingertips and toes / soles of feet after a few cycles of chemotherapy. This may be temporary and may improve after you have finished treatment. |
|
Skin rash
|
|
Hair loss
|
|
Tumour lysis syndrome (TLS) may occur as Brentuximab Vedotin may cause fast breakdown of the cancer cells.
|
|
Pancreas problems, which may lead to symptoms such as
|
|
Liver problems |
|
Lung problems |
|
Problems with normal brain function These could be symptoms of a rare but serious infection of the brain called Progressive Multifocal Leukoencephalopathy and may occur within three months of stopping treatment. |
|
Symptoms of drug allergy including one or more of the following:
|
|
Tips to help manage your condition while you are on Brentuximab Vedotin.
Exercise | Light exercise is recommended as it helps to improve mobility, balance, and even emotional well-being. Avoid strenuous exercise, and rest when you are feeling tired. |
Adequate hydration | Maintain adequate hydration with 2 to 3 litres of fluids per day unless you have been informed by your doctor to restrict fluids. This will decrease your chances of getting constipation and prevent dehydration. |
Medical and dental treatment | If you need to go to the hospital for any reason other than cancer, always inform the doctors and nurses that you are receiving anti-cancer treatment. Talk to your cancer doctor if you think you need dental treatment. Always inform your dentist that you are receiving anti-cancer treatment. |
Seek support if you feel overwhelmed
| It is normal to feel fearful or worried about your condition. Do not be afraid to talk about your concerns with your healthcare team or loved ones. There may be resources and support available to help you. |
Please take note that the above is not a complete list of all possible side effects. If you have any concerns about your medication or if you have other side effects that you think are caused by this medication, please consult your doctor or pharmacist.
If you take more than the recommended dose, please seek medical advice immediately. The information provided on this page does not replace information from your healthcare professional. Please consult your healthcare professional for more information.
This article is jointly developed by members of the National Medication Information workgroup. The workgroup consists of cluster partners (National Healthcare Group, National University Health System and SingHealth), community pharmacies (Guardian, Unity and Watsons) and Pharmaceutical Society of Singapore. The content does not reflect drug availability and supply information in pharmacies and healthcare institutions. You are advised to check with the respective institutions for such information.
Last updated on Apr 2025
This article was last reviewed on Friday, April 25, 2025